Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan + amoxicillin dual therapy guided by drug sensitivity for Helicobacter pylori eradication
ChiCTR2300075479Phase 4Not yet recruiting
- Sponsor
- Guangzhou First People's Hospital
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of vonoprazan, amoxicillin and rabeprazole in Helicobacter pylori infection (3 arms), sponsored by Guangzhou First People's Hospital. Primary endpoint: Helicobacter pylori eradication rate. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
vonoprazanamoxicillinrabeprazole
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2300075479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075479.